We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale
Product News

Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale

Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale
Product News

Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale

Image credit: Cellesce

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellesce and Hubrecht Organoid Technology (HUB) have announced a licence agreement for the expansion of organoids using Cellesce’s own bioprocessing technology and HUB Organoid Technology for the scale up of breast organoids.

Cellesce and HUB have an ongoing agreement for the expansion of organoids using HUB Technology. In a new project, funded by Innovate UK, Cellesce will expand breast cancer organoids using a combination of HUB Organoid Technology and Cellesce’s own bioprocessing technology. The project aims to confirm that breast cancer organoids remain genetically and phenotypically stable and continue to faithfully recapitulate the characteristics of the tumours from which they were originally derived. The project will provide support for the scaling of organoid expansion to generate the quantities of organoids required by commercial and academic researchers in drug discovery programmes.

Cellesce Chief Executive, Dr Mark Treherne, commented: “By partnering with HUB Cellesce will be in a position to provide an integrated drug discovery solution. This will be a comprehensive package that supplies organoids at scale which will increase the impact that organoid models are having on the cancer research community.”

“HUB Organoid Technology will benefit from Cellesce’s innovative technology to expand large quantities of organoids such as breast cancer organoids.” added Dr Rob Vries, Managing Director of the HUB.
Advertisement